Outcomes of Uretheroileal Suspension Technique During Open Radical Cystectomy
The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and th
| Condition(s) | Radical Cystectomy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The suspension technique is reported as the puboprostatic ligaments that attach the prostate to the symphysis pubis. After the ligating the complex, including both the dorsal vein complex and the puboprostatic ligaments, this complex was sharply divided anteriorly from the prostate with a safe distance (1-2 mm), and the urethra is defined and divided. After removing the prostate, the ileal pouch is reconstructed by completely everting the mucosa and sutured outward with a running 4-0 absorbable suture around the edge. The neck of the neobladder was narrowed to ≈1 cm, for convenient passage of a 20 F catheter. Anastomotic sutures of 3-0 absorbable polyglactin were placed at the 1, 3, 5, 6, 7, 9, 11 and 12 o'clock positions |
| Who can participate | Inclusion Criteria: * Patient age \>18 years. * Muscle-invasive bladder carcinoma (MIBC). * Non-muscle-invasive bladder carcinoma (NMIBC) fulfilling the following criteria: 1. \- (recurrent disease that is unresponsive to other treatments 2. \- high-grade tumors (T1, carcinoma in situ) refractory to intravesical therapy 3. -Multifocal or recurrent high-grade tumors despite intravesical therapy and the tumor progression from NMIBC to MIBC). Exclusion Criteria: * NMIBC or benign disease. * Severe hepatic renal dysfunction. * Urethral involvement with bladder carcinoma. * Poor overall health status. * Severe renal dysfunction. |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Lead sponsor | Sohag University |
| Locations | Sohag, Egypt |
| Start date | 2025-01-01 |
| NCT ID | NCT06783855 |
| Official listing | https://clinicaltrials.gov/study/NCT06783855 |